ArticleFrontiers in oncology2025

First-line treatment with cadonilimab plus paclitaxel-platinum ± bevacizumab for persistent, recurrent, or metastatic cervical cancer: a retrospective real-world study.

Xin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.